Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma

Clinical Cancer Research, 05/16/2012

Systemic treatment with bevacizumab before regional chemotherapy increases delivery of melphalan (LPAM) to tumor cells and represents a novel way to augment response to regional therapy for advanced extremity melanoma.

Print Article Summary Cat 2 CME Report